Animal health company Elanco is paying for the deal using $5.32bn in cash and $2.28bn in equity – equal to around 68 million Elanco shares.
The acquisitive company has got a bridge loan in place for the deal.
The bump in debt will see Elanco’s leverage to rocket up to
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: firstname.lastname@example.org or find out more online here.